Trial Details

TERMINATED
Basic Information
Clinical ID c1005
Identifier NCT04985968
Trial Title The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis
Interventions DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg|DRUG: Placebo
Participant Information
Sponsor InDex Pharmaceuticals
City Granada Hills
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE3
Time Information
Start Date 2021-11-24
Primary Completion Date 2023-12-20
Completion Date 2023-12-20